



Introduction to Session:
**Combined Diphtheria and Tetanus Toxoids and Acellular
Pertussis, Inactivated Poliovirus, *Haemophilus influenzae*
Type b Conjugate, and Hepatitis B vaccine (Vaxelis)**

Jamie Loehr, MD
Chair, ACIP Hib/Meningococcal Vaccines Work Group

June 26, 2024

ACIP Meningococcal/Hib Vaccines Work Group

- ACIP Members on the WG
 - Jamie Loehr (Chair)
 - Wilbur Chen
- Ex Officio WG Members
 - Margaret Bash (FDA)
 - Matthew Clark (IHS)
 - Xin-Xing Gu (NIH)
- WG Liaisons and Consultants
 - Amra Resic (AAFP)
 - Mary Healy (AAP)
 - Barb Fluty (ACHA)
 - Karyn Lyons (AIM)
 - Paul Cieslak (CSTE)
 - Kathy Hsu (IDSA)
 - Pamela Doyon-Plourde (NACI)
 - Jeff Goad (NFID)
 - Jessica Cataldi (PIDS)
 - Amy Middleman (SAHM)
 - Kathy Poehling (Wake Forest)
 - Lynn Bahta (Minnesota Department of Health)
 - David Stephens (Emory)
- GRADE/EtR Support
 - Doug Campos-Outcalt (Arizona)
 - Rebecca Morgan (Case Western Reserve)
- CDC Contributors
 - Jennifer Collins (DBD/NCIRD)
 - Sarah Schillie (DBD/NCIRD)
 - Lucy McNamara (DBD/NCIRD)
 - LeAnne Fox (DBD/NCIRD)
 - Susan Hariri (DBD/NCIRD)
 - Amy Rubis (DBD/NCIRD)
 - Gabrielle Cooper (DBD/NCIRD)
 - Noele Nelson (DBD/NCIRD)
 - Alison Albert (DBD/NCIRD)
 - Shelby Miller (DBD/NCIRD)
 - Marc Fischer (DIDRI/NCEZID)
 - Xiaoyu Dong (ISD/NCIRD)
 - Andrew Leidner (ISD/NCIRD)
 - Ismael Ortega-Sanchez (CORVD/NCIRD)
 - Jonathan Duffy (DHQP/NCEZID)
 - Pedro Moro (DHQP/NCEZID)
 - Tanya Myers (DHQP/NCEZID)
 - Liz Velazquez (ISD/NCIRD)
 - Jessica MacNeil (ACIP Secretariat)
 - Hannah Rosenblum (ACIP Secretariat)
 - Melinda Wharton (ACIP Secretariat)

Background

- PRP-OMP (PedvaxHIB) is preferentially recommended for American Indian and Alaska Native (AI/AN) infants
 - It provides a protective antibody response after the first dose
 - Historically, Hib meningitis peaked at an earlier age among AI/AN infants
- Vaxelis (DTaP-IPV-Hib-HepB) does not currently have a preferential recommendation for AI/AN infants because
 - It contains PRP-OMP in a lower amount than PedvaxHIB
 - Post-dose 1 immunogenicity data were not previously available

Policy question

Should DTaP-IPV-Hib-HepB (Vaxelis) be included with PRP-OMP (PedvaxHIB) in the preferential recommendation for American Indian and Alaska Native (AI/AN) infants based on the Hib component?

February 2024 ACIP Meeting Presentations

- Epidemiology of invasive Hib disease in AI/AN populations and evidence supporting the existing preferential recommendation for PedvaxHIB
- Clinical trial data on post-dose 1 immunogenicity of Vaxelis vs. PedvaxHIB
- Preliminary Work Group considerations

Today's agenda

Topic	Presenter
Evidence to Recommendations and Proposed Recommendations: Use of Vaxelis among American Indian and Alaska Native Infants	Dr. Jennifer Collins (CDC/NCIRD)
Updated Vaccines for Children (VFC) Resolution	Dr. Jeanne Santoli (CDC/NCIRD)

All topics will be presented for information, discussion, and vote